Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

This is an interventional treatment trial for Anemia of Chronic Kidney Disease focused on measuring Hepcidin, Hemoglobin, Iron, Anemia of chronic disease Read More

Inclusion Criteria:

• Patients with stage 5 CKD having been on hemodialysis for at least 90 days;
• Male and post-menopausal (no menses for at least 12 months without an alternative medical cause) female patients with an age of ≥18 years and with a maximum body weight of 85 kg;
• Patients being on stable erythropoiesis stimulating agent dose for 4 weeks prior to Screening;
• Patients being on stable oral or intravenous iron doses for 4 weeks prior to Screening;
• Mean of 3 Hb values during the screening period, each obtained at least 7 days apart must be ≤10.5 g/dL, with a difference of ≤1.0 g/dL between the lowest and highest value;
• Serum ferritin concentration ≥300 ng/mL;
• Transferrin saturation ≤30%;
• Plasma hepcidin concentration at least 5 nmol/L;
• Screening serum folate and vitamin B12 ≥lower limit of normal Hepcidin 5 - 50 nmol/L;
• Male patients with a female partner of childbearing potential agree to use a medically acceptable method of contraception (e.g., condoms, sexual abstinence, vasectomy), not including the rhythm method for 30 days after administration of the study medication; and
• The patient is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form (ICF). Patient agrees to comply with the protocol-mandated procedures and visits.

Exclusion Criteria:

• Anemia due to causes other than chronic kidney disease, including hemoglobinopathies, hemolytic anemias, myelodysplasia or malignancy;
• Blood transfusion within 2 months before administration of study medication;
• Previous enrollment in this study;
• Patients treated with PRS-080#022-DP in a previous clinical study;
• Current or previous (within 60 days or 5 half-lives before study medication administration) treatment with another investigational drug and/or medical device or participation in another clinical study;
• Employees of the sponsor or patients who are employees or relatives of the investigator;
• Known allergy to any component of the PRS-080#022-DP formulation;
• Positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus antibody (anti-hepatitis C virus Ab), or human immunodeficiency virus (HIV), serology test results not older than 3 months are accepted;
• Planned surgery during the study period;
• Known or suspected active infection;
• Active or chronic gastrointestinal bleeding, or known coagulation disorder;
• Unwilling or unable to comply with the protocol, in the judgment of the investigator;
• Unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty/stents, apoplexy (sudden circulatory disturbances of an organ or specific region of the body) or coronary artery bypass grafting <3 months prior to Screening;
• Congestive heart failure: New York Heart Association Class III or IV;
• Peripheral arterial disease with necrosis, stage IV (Fontaine) or grade III (category 5 and 6, Rutherford); and
• Any medical condition that in the judgment of the investigator might interfere with study participation or jeopardize patient's safety during the study (e.g., active infection).